dehydrosanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dehydrosanol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	72070
CHEMBL ID	2104003
CHEBI ID	135640
SCHEMBL ID	564338
MeSH ID	M0055369

Synonyms (32)

Synonym
1824-52-8
bemetizide
dehydrosanol
2h-1,2,4-benzothiadiazine, 3,4-dihydro-6-chloro-3-(alpha-methylbenzyl)-7-sulfamoyl-, 1,1-dioxide
brn 0631888
einecs 217-357-5
6-chlor-3,4-dihydro-3-(alpha-methylbenzyl)-7-sulfamoyl-2h-1,2,4-benzothiadiazine-1,1-dioxide
bemetizid
6-chloro-3,4-dihydro-3-(alpha-methylbenzyl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
bemetizidum [inn-latin]
pertensosanol
diu 60
bemetizide [inn:ban]
bemeticide
su 7078
bemetizida [inn-spanish]
CHEBI:135640
bemetizidum
ezn4d2o31b ,
bemetizida
unii-ezn4d2o31b
CHEMBL2104003
SCHEMBL564338
bemetizide [mart.]
6-chloro-3,4-dihydro-3-(.alpha.-methylbenzyl)-2h-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
bemetizide [inn]
bemetizide [who-dd]
Q27277448
6-chloro-1,1-dioxo-3-(1-phenylethyl)-3,4-dihydro-2h-1lambda6,2,4-benzothiadiazine-7-sulfonamide
DTXSID301021632
DTXSID30862759
6-chloro-1,1-dioxo-3-(1-phenylethyl)-1,2,3,4-tetrahydro-1lambda~6~,2,4-benzothiadiazine-7-sulfonamide

Research Excerpts

Compound-Compound Interactions

Excerpt	Reference	Relevance
"The optimal daily dose and dose regimen of a new drug combination (Pertenso), consisting of 10 mg bemetizide, 20 mg triamterene, 20 mg dihydralazine and 20 mg bupranolol were tested in 14 hypertensive outpatients (WHO I to III) in a single blind crossover trial."	( [Treatment of hypertension with a drug combination, consisting of bemetizide, triamterene, dihydralazine and bupranolol (author's transl)]. Brandstetter, G; Gasser, RW; Skrabal, F, 1982)	0.26

Dosage Studied

Excerpt	Relevance	Reference
" Thus, this long-term study provides additional evidence that diuretics have a flat dose-response curve with respect to their antihypertensive efficacy, whereas lower doses might cause less pronounced activation of counter-regulatory systems."	( Long-term diuretic therapy: effects of dose reduction on antihypertensive efficacy and counterregulatory systems. Ripka, O; Weisser, B, 1992)	0.28

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
benzothiadiazine	Heterocyclic compound of a ring with sulfur and two nitrogen atoms fused to a benzene ring. Members inhibit sodium-potassium-chloride symporters and are used as diuretics.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (18)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15 (83.33)	18.7374
1990's	2 (11.11)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (5.56)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	32.03 (24.57)
Research Supply Index	3.40 (2.92)
Research Growth Index	4.13 (4.65)
Search Engine Demand Index	36.59 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (32.03)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	9 (45.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (5.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (50.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	3.35	1	1	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
bupranolol Bupranolol: An adrenergic-beta-2 antagonist that has been used for cardiac arrhythmia, angina pectoris, hypertension, glaucoma, and as an antithrombotic.	5.36	5	3	aromatic ether
cyclopenthiazide Cyclopenthiazide: Thiazide diuretic also used as an antihypertensive agent.	3.35	1	1	benzothiadiazine
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	3.34	1	1	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	3.34	1	1	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	4.31	2	2	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	1.96	1	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	3.74	2	1	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	6.61	10	6	pteridines	diuretic; sodium channel blocker
aldosterone [no description available]	3.36	1	1	11beta-hydroxy steroid; 18-oxo steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; mineralocorticoid; primary alpha-hydroxy ketone; steroid aldehyde	human metabolite; mouse metabolite
dihydralazine Dihydralazine: 1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)	3.34	1	1	phthalazines
silver Silver: An element with the atomic symbol Ag, atomic number 47, and atomic weight 107.87. It is a soft metal that is used medically in surgical instruments, dental prostheses, and alloys. Long-continued use of silver salts can lead to a form of poisoning known as ARGYRIA.	2.15	1	0	copper group element atom; elemental silver	Escherichia coli metabolite
quercetin [no description available]	2.15	1	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	1.96	1	0	prostaglandins E	human metabolite; mouse metabolite; oxytocic
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	1.94	1	0

Condition	Relationship Strength	Studies	Trials
Anasarca [description not available]	2.35	2	0
Blood Clot [description not available]	2.35	2	0
Edema Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.	7.35	2	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.35	2	0
Blood Pressure, High [description not available]	6.75	10	7
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	6.75	10	7
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	4.96	3	3
Fetal Death Death of the developing young in utero. BIRTH of a dead FETUS is STILLBIRTH.	1.96	1	0
Embryopathies [description not available]	1.96	1	0
Edema-Proteinuria-Hypertension Gestosis [description not available]	1.96	1	0
Pre-Eclampsia A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.	1.96	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	1.96	1	0
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	4.05	3	1
Hypertension, Renal Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.	3.34	1	1
Chronic Kidney Failure [description not available]	1.98	1	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	1.98	1	0

chemdatabank.com